Premium
Significance of p53‐binding protein 1 (53 BP 1) expression in thyroid papillary microcarcinoma: association with BRAF V 600E mutation status
Author(s) -
Mussazhanova Zhanna,
Matsuda Katsuya,
Naruke Yuki,
Mitsutake Norisato,
Stanojevic Boban,
Rougounovitch Tatiana,
Saenko Vladimir,
Suzuki Keiji,
Nishihara Eijyun,
Hirokawa Mitsuyoshi,
Ito Masahiro,
Nakashima Masahiro
Publication year - 2013
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12233
Subject(s) - carcinogenesis , thyroid carcinoma , pathology , thyroid , immunohistochemistry , immunofluorescence , mutation , medicine , cancer research , biology , cancer , gene , antibody , immunology , genetics
Aims In a previous report, we proposed that analysis of 53 BP 1 expression by immunofluorescence could be a useful tool in estimating the level of genomic instability ( GIN ), as well as the malignant potential, of thyroid tumours. In an attempt to clarify the value of 53 BP 1 expression as a new molecular marker for the aggressiveness of thyroid papillary microcarcinoma ( PMC ), we assessed the association between the type of 53 BP 1 expression and clinicopathological features such as tumour size, extrathyroidal invasion, lymph node metastasis and BRAF V600E mutation of PMC . Methods and results A total of 36 surgically resected thyroid tumours, including 13 PMC and 23 conventional papillary thyroid carcinomas ( PTC ), were available for this study. Analysis using immunofluorescence revealed that the incidence of an abnormal or high DNA damage response ( DDR ) type of 53 BP 1 expression was significantly higher in PTC than PMC . BRAF V600E mutation was not associated significantly with tumour aggressiveness in either PMC or PTC cases. Abnormal/high DDR type of 53 BP 1 expression was associated closely with both BRAF V600E mutation and papillary and/or trabecular architecture of PMC . Conclusions Abnormal/high DDR type of 53 BP 1 expression might be associated with GIN and papillary/trabecular morphology at an early stage of PTC carcinogenesis through BRAF V600E mutation.